ClinicalTrials.gg
Drug

Faricimab clinical trials

Also written RO6867461, VABYSMO™ and RG7716.

studies test it
46
open now
19
in phase 3
18
first study started
2006

How each study uses faricimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the faricimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Jan 2022 · VABYSMO · BLA 761235 (FDA, Drugs@FDA)
European Union
15 Sept 2022 · Vabysmo · EMEA/H/C/005642 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Faricimab
26
intravitreal injection
5
Faricimab Injection [Vabysmo]
5
faricimab-svoa
3
Faricimab Injection
3

Brand

VABYSMO™
16

Development codes

RO6867461
17
RG7716
15

Studies by the year they started

46 studies that test it; most in 2026 (8)

Studies that test faricimab, by start year
YearStudies
20062
20071
20081
20131
20151
20161
20171
20182
20192
20203
20213
20223
20235
20245
20257
20268

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
9
Phase 3
18
Phase 4
14
No phase
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 29

Hoffmann-La Roche (16) · Singapore National Eye Centre (2) · Jaeb Center for Health Research (2) · Asociación para Evitar la Ceguera en México (2) · Genentech, Inc. (1) · McMaster University (1) · Greater Houston Retina Research (1) · Bojie Hu (1)

Often tested with

Tested in the same studies.

KH902 fusion protein (1) · Ranibizumab (1) · Bevacizumab (1) · Fluocinolone Acetonide (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test faricimab.

Studies

Open first, then newest update. How each study uses faricimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test faricimab →

Given beside what is tested · 2 — faricimab is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with faricimab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call faricimab · ClinicalTrials.gg INT001944

  • MeSH (NLM) C000723200faricimabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) QC4F7FKK7IFARICIMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2591519One source FDA
  • Wikidata Q60785557faricimabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174885FaricimabOne source FDA
  • DrugBank DB15303One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.